[Molecular diagnostics of lung cancer].
Development of the target therapies of lung cancer was a rapid process which fundamentally changed the pathological diagnosis as well. Furthermore, molecular pathology became essential part of the routine diagnostics of lung cancer. These changes generated several practical problems and in underdeveloped countries or in those with reimbursement problems have been combined with further challenges. The central and eastern region of Europe are characterized by similar problems in this respect which promoted the foundation of NSCLC Working Group to provide up to date protocols or guidelines. This present paper is a summary of the molecular pathology and target therapy guidelines written with the notion that it has to be upgraded continuously according to the development of the field.
The Fingerland Department of Pathology, Charles University, Hradec Kralove, Czech Republic.
A
A
Ryska
Department of Radiation Therapy and Oncology, Gdansk Medical University, Gdansk, Poland.
R
R
Dziadziuszko
Maria Sklodovska-Curie Institute, Oncology Center, Warshaw, Poland.
W
W
Olszewski
Spec. Hospital St Zoerardus Zobor, Nitra, Slovakia.
P
P
Berzinec
Istambul University, Istambul, Turkey.
B
B
Öz
Department of Lung Cancer, Meir Hospital, Tel Aviv, Israel.
M
M
Gottfried
University Clinic Golnic, University of Ljubjana, Ljubjana, Slovenia.
T
T
Cufer
Poliklinika Apnea, Zagreb, Croatia.
M
M
Samarzija
Department of Pathology, Comenius University, Martin, Slovakia.
L
L
Plank
National Korányi Lung Institute, Budapest, Hungary.
Gy
G
Ostoros
2nd Department of Pathology, Semmelweis University, Budapest, Hungary.
J
J
Tímár
D000077548:Anaplastic Lymphoma Kinase; D002289:Carcinoma, Non-Small-Cell Lung / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D032921:Consensus; D066246:ErbB Receptors / Q000235:genetics; D005060:Europe; D015321:Gene Rearrangement; D006801:Humans; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy / Q000235:genetics*; D058990:Molecular Targeted Therapy / Q000379:methods; D009154:Mutation; D057089:Pathology, Molecular / Q000379:methods; D010348:Patient Care Team; D017410:Practice Guidelines as Topic; D011518:Proto-Oncogene Proteins / Q000235:genetics; D016283:Proto-Oncogene Proteins p21(ras); D020794:Receptor Protein-Tyrosine Kinases / Q000235:genetics; D018631:ras Proteins / Q000235:genetics
C117307:KRAS protein, human; D011518:Proto-Oncogene Proteins; D000077548:Anaplastic Lymphoma Kinase; D066246:ErbB Receptors; D020794:Receptor Protein-Tyrosine Kinases; D016283:Proto-Oncogene Proteins p21(ras); D018631:ras Proteins